Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin

Bookmark and Share
Published: 3 Jun 2016
Views: 2436
Dr Hope Rugo - University of California, San Francisco, USA

Dr Rugo talks to ecancertv at ASCO​ 2016 about a randomised double blind phase III safety and efficacy trial of the proposed trastuzumab biosimilar, MYL-1401O vs. herceptin.

MYL-1401O is comparable in efficacy and safety to the FDA-approved targeted breast cancer drug trastuzumab in women with HER2-positive advanced breast cancer, according to the randomised phase III study.

Watch the press conference here and read the news story for more.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.